3 Reasons To Dump AstraZeneca plc For GlaxoSmithKline plc

AstraZeneca plc’s (LON: AZN) recent rally has been impressive but it could be time to sell out in favour of GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One of the FTSE 100’s best performers so far this year has been AstraZeneca (LSE: AZN) (NYSE: AZN.US). Indeed, year to date, AstraZeneca has rallied nearly 10%, surging ahead of its peer GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), which has only returned 1% during the same period.

However, AstraZeneca’s impressive run, it could be time for investors to take profits. 

Future growth

AstraZeneca has outperformed during the last few months thanks to renewed optimism about experimental mental cancer therapies. In particular, investors have been pleased with early-stage trials of the company’s immuno-oncology treatment, which aims to treat cancer patients by boosting their immune system.

astrazenecaUnfortunately, this cancer therapy is not expected to file for regulatory approval much before 2017, which means that AstraZeneca is likely to lose a significant chuck of the market to rivals during this time. What’s more, AstraZeneca’s’ own management does not believe that the company’s overall sales will return to growth until 2017 and over the next three years sales are going to decline further before they start to mover higher.

In comparison. GlaxoSmithKline’s earnings are sales are expected to remain fairly stable over the next few years as the company cuts costs, brings new treatments to market and buys backs shares. 

Still, unlike GlaxoSmithKline AstraZeneca’s treatment sales to China are still expanding, although this is not enough to offset declining sales in other regions around the world as treatments come off patent.

Pipeline

Biotechnology companies like AstraZeneca rely upon their treatment pipelines to drive future growth and boost earnings. Unfortunately, AstraZeneca’s treatment pipeline lacks that of GlaxoSmithKline and the latter is making solid progress bringing new products to market.

GlaxoSmithKlineFor example, GlaxoSmithKline had five new drugs approved for sales during 2013 and a further 40 are in the process of coming to market. Meanwhile, AstraZeneca does not expect to have any new products file for regulatory approval before 2016.

Actually, GlaxoSmithKline’s pipeline of drugs has been called the ‘best in class’ and ‘sector leading by many analysts, putting the company ahead of many of its larger international peers, such as Johnson & Johnson.

Valuation

As AstraZeneca is not expected to return to growth until 2017, in theory the company should trade at a lower valuation than GlaxoSmithKline, as GlaxoSmithKline’s prospects for growth are more promising. This is not the case. Specifically, at present levels, AstraZeneca is trading at a forward P/E of 15.5 for 2014, while GlaxoSmithKline trades at a forward P/E of 14.6.

What’s more, according to City forecasts GlaxoSmithKline’s current share price means the company is trading at 13.6 times 2015 earnings, while AstraZeneca  is trading at 15.7 times, despite the fact the company’s profits are expected to slide. So, it would appear that GlaxoSmithKline is relatively undervalued compared to AstraZeneca.

Further, GlaxoSmithKline currently offers a dividend yield of 4.8%, forecast to rise to 5.2% during 2015. AstraZeneca only offers a yield of 4.2%, forecast to rise 4.3%. All in all, AstraZeneca’s current premium over GlaxoSmithKline really looks unwarranted. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

More on Investing Articles

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »